Suchergebnisse - Ray Lin

  • Treffer 1 - 5 von 5
Treffer weiter einschränken
  1. 1
    NMDA Receptors Mediate Olfactory Learning and Memory in Drosophila

    NMDA Receptors Mediate Olfactory Learning and Memory in Drosophila von Shouzhen Xia, Tomoyuki Miyashita, Tsai‐Feng Fu, Wei‐Yong Lin, Chia‐Lin Wu, Lori Pyzocha, Inn-Ray Lin, Minoru Saitoe, Tim Tully, Ann‐Shyn Chiang

    Veröffentlicht 2005
    Volltext Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:
  2. 2
    Phase I Dose-Escalation Study of Taselisib, an Oral PI3K Inhibitor, in Patients with Advanced Solid Tumors

    Phase I Dose-Escalation Study of Taselisib, an Oral PI3K Inhibitor, in Patients with Advanced Solid Tumors von Dejan Juric, Ian E. Krop, Ramesh K. Ramanathan, Timothy R. Wilson, Joseph A. Ware, Sandra Sanabria Bohórquez, Heidi Savage, Deepak Sampath, Laurent Salphati, Ray Lin, Huan Jin, Hema Parmar, Jerry Y. Hsu, Daniel D. Von Hoff, José Baselga

    Veröffentlicht 2017
    Volltext Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:
  3. 3
    First-in-Human Phase I Study of Pictilisib (GDC-0941), a Potent Pan–Class I Phosphatidylinositol-3-Kinase (PI3K) Inhibitor, in Patients with Advanced Solid Tumors

    First-in-Human Phase I Study of Pictilisib (GDC-0941), a Potent Pan–Class I Phosphatidylinositol-3-Kinase (PI3K) Inhibitor, in Patients with Advanced Solid Tumors von Debashis Sarker, Joo Ern Ang, Richard D. Baird, Rebecca Kristeleit, Krunal Shah, Víctor Moreno, Paul A. Clarke, Florence I. Raynaud, Gallia G. Levy, Joseph A. Ware, Kathryn Mazina, Ray Lin, Jenny Wu, Jill Fredrickson, Jill M. Spoerke, Mark R. Lackner, Yibing Yan, Lori S. Friedman, Stan B. Kaye, Mika K. Derynck, Paul Workman, Johann S. de Bono

    Veröffentlicht 2014
    Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:
  4. 4
    Phase Ia study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) in patients with recurrent advanced solid tumors

    Phase Ia study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) in patients with recurrent advanced solid tumors von Asha Nayak-Kapoor, Zhonglin Hao, Ramses Sadek, Robin Dobbins, Lisa Marshall, Nicholas N. Vahanian, W. Jay Ramsey, Eugene P. Kennedy, Mario R. Mautino, Charles J. Link, Ray Lin, Stephanie Royer‐Joo, Xiaorong Liang, Laurent Salphati, Kari M. Morrissey, Sami Mahrus, Bruce McCall, Andrea Pirzkall, David H. Munn, John E. Janik, Samir N. Khleif

    Veröffentlicht 2018
    Volltext Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:
  5. 5
    Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors

    Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors von Kyung Hae Jung, Patricia LoRusso, Howard A. Burris, Michael A. Gordon, Yung‐Jue Bang, Matthew D. Hellmann, Andrés Cervantes, María Ochoa de Olza, Aurélien Marabelle, F. Stephen Hodi, Myung‐Ju Ahn, Leisha A. Emens, Fabrice Barlési, Omid Hamid, Emiliano Calvo, David F. McDermott, Hatem Soliman, Ina Rhee, Ray Lin, Tony Pourmohamad, Julia Suchomel, Amy Lew Tsuhako, Kari M. Morrissey, Sami Mahrus, Roland Morley, Andrea Pirzkall, S. Lindsey Davis

    Veröffentlicht 2019
    Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:

Suchwerkzeuge: